Security key
641288105
NeuroPace Inc - Common Stock, $0.01 par value (NPCE)
CUSIP: 641288105
Q4 2022 13F Holders as of 31 Dec 2022
- Security type / class
- Equity / Common Stock, $0.01 par value
- Total 13F shares
- 17,357,024
- Total 13F value
- $25,862,002
- Share change
- -761,021
- SEC-reported price per share
- $1.49
- Number of holders
- 22
- Value change
- -$2,680,436
- Number of buys
- 11
- Number of sells
- 9
- Shares outstanding
- 34,317,804
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2022
Institutions
22
Top holders
10
NPCE full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2026
NeuroPace Inc SEC filings
NeuroPace Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 641288105
Recent filing periods:
Ownership snapshot
Top reported holders of NPCE - NeuroPace Inc - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Accelmed Partners II L.P.
Disclosed value leader
Accelmed Partners II L.P.
Comparable rows
0/15
Latest evidence
21 Nov 2022
3/4/5
13F
Highest disclosed value: $44,878,722
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Accelmed Partners II L.P. has the largest disclosed position value at $44.88M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Accelmed Partners II L.P.'s linked filing trail.
Disclosed position value
Top 5
Accelmed Partners II L.P.
$44.88M
KCK LTD.
$21.08M
ORBIMED ADVISORS LLC
$15.05M
Soleus Capital Management, L.P.
$8.75M
MORGAN STANLEY
$7.96M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Accelmed Partners II L.P. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$44,878,722
4,432,948 shares
|
— | 21 Nov 2022 |
| KCK LTD. |
13F
Company
|
—
denominator unverified
|
$21,079,000
5,621,111 shares
|
— | 30 Sep 2022 |
| ORBIMED ADVISORS LLC |
13F
Company
|
—
denominator unverified
|
$15,046,000
4,012,281 shares
|
— | 30 Sep 2022 |
| Soleus Capital Management, L.P. |
13F
Company
|
—
denominator unverified
|
$8,753,000
2,334,003 shares
|
— | 30 Sep 2022 |
| MORGAN STANLEY |
13F
Company
|
—
denominator unverified
|
$7,963,000
2,123,599 shares
|
— | 30 Sep 2022 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
—
denominator unverified
|
$2,195,000
585,367 shares
|
— | 30 Sep 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
22
Shares
17,357,024
Rows available
22
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2022 vs Q3 2022 Across Filers
Q3 2022 holders
27
Q4 2022 holders
22
Holder diff
-5
| Investor | Q3 2022 Shares | Q4 2022 Shares | Share Diff | Share Chg % | Q3 2022 value | Q4 2022 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend